


Name	Rheun-Chuan Lee	
Organization	Taipei Veterans General Hospital	
Title	MD	

**CURRENT POSITIONS:**

Chief, division of Abdominal Radiology, Department of Radiology, Taipei Veterans General Hospital

**EDUCATIONAL AND CAREER EXPERIENCES**

1. He has developed his professional training experience with the Taipei Veterans General Hospital in the department of Radiology and Gastrointestinal Radiology.
2. Overseas experience includes being a Research Fellow in MRI center in the Hospital of the University of Pennsylvania, USA, Living Donor Liver Transplant Imaging and Intervention training with the National Kyoto University Hospital, Kyoto, Japan, Yttrium-90 microspheres therapy training at St. Vincent Hospital Sydney in Australia and William Beaumont Hospital in USA.
3. His research and personal interests include Liver-directed therapy, including TACE, Drug-eluting microspheres, Yttrium-90 microspheres therapy and contrast media.

**RECENT PUBLICATIONS related to HCC**

1. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. *J Clin Oncol*. 2018 Jul 1;36(19):1913-1921.
2. Combined Yttrium-90 microsphere selective internal radiation therapy and external beam radiotherapy in patients with hepatocellular carcinoma: From clinical aspects to dosimetry. *PLoS One*. 2018 Jan 2;13(1):e0190098.
3. Three-dimensional Quantitative Color-coding Analysis on Hepatic Arterial Flow Change during Chemoembolization of Hepatocellular Carcinoma. *J Vasc Interv Radiol*. 2018; 29:1362–1368.
4. Metastasis in patients with hepatocellular carcinoma: Prevalence, determinants, prognostic impact and ability to improve the Barcelona Clinic Liver Cancer system. *Liver Int*. 2018;38:1803–1811.
5. Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. *Liver Cancer*. 2018 Oct;7(4):312-322.
6. The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. *Ann Surg Oncol*. 2017 Sep;24(9):2465-2473.
7. A New Treatment-integrated Prognostic Nomogram of the Barcelona Clinic Liver Cancer System for Hepatocellular Carcinoma. *Sci Rep*. 2017 Aug 11;7(1):7914.
8. Prognostic role of noninvasive liver reserve markers in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. *PLoS One*. 2017 Jul 3;12(7):e0180408.
9. Quantitative Real-Time Fluoroscopy Analysis on Measurement of the Hepatic Arterial Flow During Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma: Comparison with Quantitative Digital Subtraction Angiography Analysis. *Cardiovasc Intervent Radiol*. 2016 ;39(11):1557-1563.
10. Nomogram of the Barcelona Clinic Liver Cancer system for individual prognostic prediction in hepatocellular carcinoma. *Liver Int*. 2016 Oct;36(10):1498-506.
11. Consensus for Radiotherapy in Hepatocellular Carcinoma from The 5th Asia-Pacific Primary Liver Cancer

- Expert Meeting (APPLE 2014): Current Practice and Future Clinical Trials. *Liver Cancer*. 2016 Jul;5(3):162-74.
12. Current role of selective internal radiation with yttrium-90 in liver tumors. *Future Oncol*. 2016 May;12(9):1193-204.
  13. Objective Measurement of Arterial Flow Before and After Transcatheter Arterial Chemoembolization: A Feasibility Study Using Quantitative Color-Coding Analysis. *Cardiovasc Intervent Radiol*. 2015 Dec;38(6):1494-501.
  14. The Effectiveness of ART Score in Selecting Patients for Transarterial Chemoembolization Retreatment: A Cohort Study in Taiwan. *Medicine (Baltimore)*. 2015 Nov;94(47):e1659.
  15. Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma. *J Surg Oncol*. 2015 Mar 15;111(4):404-9.
  16. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. *Int J Radiat Oncol Biol Phys*. 2012 Jan 1;82(1):401-7.
  17. Model-based radiation dose correction for yttrium-90 microsphere treatment of liver tumors with central necrosis. *Int J Radiat Oncol Biol Phys*. 2011 Nov 1;81(3):660-8.